Dyrk1A Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
DYRK1A is a serine/threonine kinase that plays crucial roles in neuronal development, synaptic plasticity, and tau phosphorylation. It has emerged as a significant therapeutic target for Alzheimer's disease and other neurodegenerative disorders due to its involvement in multiple pathogenic pathways [1]. [1]
DYRK1A is a gene/protein encoding a key neuronal protein involved in synaptic function, signal transduction, and cellular homeostasis. Dysfunction of DYRK1A is associated with neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and related disorders. [2]
DYKL1A is a 754-amino acid protein kinase belonging to the CMGC family of serine/threonine kinases. The protein contains: [3]
The kinase is highly conserved across species and is located primarily in the nucleus, but also associates with cellular membranes and the cytoskeleton. [^5]
DYRK1A is crucial for normal brain development and function:
As a tau kinase, DYRK1A phosphorylates tau at multiple sites:
The kinase regulates synaptic proteins and signaling pathways important for learning and memory:
DYRK1A is significantly upregulated in AD brains:
DYRK1A is located on chromosome 21, explaining its overexpression in Down syndrome:
In PD models:
Several DYRK1A inhibitors are in development:
| Compound | Company | Stage | Notes |
|---|---|---|---|
| Harmine | Natural product | Preclinical | First-generation inhibitor |
| DYRK1A-IN-1 | Various | Preclinical | Selective inhibitor |
| AZ 191 | AstraZeneca | Preclinical | Brain-penetrant |
| DYR-1a | Ongoing | Discovery | Clinical candidate |
The study of Dyrk1A Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
While no DYRK1A inhibitors have reached clinical trials for neurodegeneration yet:
Gene therapy: RNAi-based approaches to reduce expression. Gene therapy. ↩︎
Combination therapy: DYRK1A inhibition with anti-amyloid or anti-tau approaches. Combination therapy. ↩︎
Ahn: Lee Y, et al. DYRK1A promotes tau phosphorylation and aggregation in AD. 2016. ↩︎